Richard Smith, DO
Hospitalist · Columbia, SCNPI 1043730468
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 31.5% of the total. 2025 is the largest year on record at $641, more than ten times the $17 reported in 2020. Among hospitalist clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$682
- Novo Nordisk$644
- GSK$156
- Lilly USA, LLC$119
- AstraZeneca$116
- Novartis$87
- plus $359 from 13 others
What the payments were for
- Food & beverage$2,162100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $682 |
| Novo Nordisk | 40 | $644 |
| GSK | 9 | $156 |
| Lilly USA, LLC | 8 | $119 |
| AstraZeneca | 7 | $116 |
| Novartis | 5 | $87 |
| Stryker | 1 | $60 |
| Amgen | 3 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Dynavax Technologies Corporation | 2 | $37 |
| Bayer | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Boehringer Ingelheim | 1 | $23 |
| Verona Pharma, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Cequr Corporation | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$115
How this compares
$2,162 in reported general payments places this provider in the 95th percentile of 398 hospitalist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $212,241 |
| MounjaroTirzepatide | 79 | $116,399 |
| JardianceEmpagliflozin | 93 | $113,740 |
| EliquisApixaban | 78 | $87,478 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $80,458 |
| EntrestoSacubitril/Valsartan | 33 | $47,297 |
| TrulicityDulaglutide | 22 | $47,160 |
| LinzessLinaclotide | 41 | $45,288 |
| FarxigaDapagliflozin Propanediol | 44 | $33,070 |
| XareltoRivaroxaban | 19 | $30,756 |
| MyrbetriqMirabegron | 35 | $29,755 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $22,324 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $18,324 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $16,515 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $15,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $644 | $212,241169 claims |
| Lilly USA, LLCMounjaro, Trulicity | $119 | $163,559101 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $23 | $145,784123 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $156 | $109,21993 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $116 | $53,89766 claims |
| NovartisEntresto | $87 | $47,29733 claims |
| AbbVieLinzess, Synthroid | $682 | $47,17760 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 398 hospitalist providers in South Carolina.
Other hospitalist in Columbia
- Harmeet GillColumbia$2K
- William LindseyColumbia$2K
- Christopher BallouColumbia$1K
- Colin WidenerColumbia$870
- James FieldsColumbia$791
- Peter CarnohanColumbia$743
- Nanik RamColumbia$648
- Sidney RhoadesColumbia$634
- Michael TaylorColumbia$619
- Cedric RiversColumbia$541
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.